Systematic review on tuberculosis risk in patients with rheumatoid arthritis receiving inhibitors of Janus Kinases.

Published in: Expert opinion on drug safety (2020)

Available data on anti-JAKs suggest a negligible risk of active TB occurrence in low endemic areas.

Keyphrases